1,095 research outputs found
Dynamic sampling schemes for optimal noise learning under multiple nonsmooth constraints
We consider the bilevel optimisation approach proposed by De Los Reyes,
Sch\"onlieb (2013) for learning the optimal parameters in a Total Variation
(TV) denoising model featuring for multiple noise distributions. In
applications, the use of databases (dictionaries) allows an accurate estimation
of the parameters, but reflects in high computational costs due to the size of
the databases and to the nonsmooth nature of the PDE constraints. To overcome
this computational barrier we propose an optimisation algorithm that by
sampling dynamically from the set of constraints and using a quasi-Newton
method, solves the problem accurately and in an efficient way
Outcomes with ibrutinib by line of therapy and postâibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as firstâline therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higherârisk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinibâtreated patients based on prior lines of therapy, including after ibrutinib discontinuation. Data were analyzed from two multicenter phase 3 studies of singleâagent ibrutinib: RESONATE (PCYCâ1112) in patients with R/R CLL and RESONATEâ2 (PCYCâ1115) in patients with treatmentânaive (TN) CLL without del(17p). This integrated analysis included 271 ibrutinibâtreated nonâdel(17p) patients with CLL (136 TN and 135 R/R). Median progressionâfree survival (PFS) was not reached for subgroups with 0 and 1/2 prior therapies but was 40.6 months for patients with â„3 therapies (median followâup: TN, 36âmonths; R/R, 44âmonths). Median overall survival (OS) was not reached in any subgroup. Overall response rate (ORR) was 92% in TN and 92% in R/R, with depth of response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to AEs were similar between patient groups. Most patients (64%) remain on treatment. OS following discontinuation was 9.3 months in R/R patients (median followâup 18âmonths, nâ= 51) and was not reached in TN patients (median followâup 10 months, nâ= 30). In this integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib discontinuation were for patients receiving ibrutinib in earlier lines of therapy
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3KÎŽ inhibition
The majority of chronic lymphocytic leukemia (CLL) patients are diagnosed with early-stage disease but the currently used prognostic tools appear to be less informative in this group of patients.1 This is especially problematic for patients with mutated immunoglobulin genes (M-CLL) as they have a more diverse clinical course when compared with patients with unmutated immunoglobulin genes (U-CLL).1, 2, 3, 4 Given the emergence of promising targeted, less toxic, therapeutics in CLL,5, 6 there is an increased need to identify patients who might benefit from early treatment with these new agents
Patient-Reported Outcome questionnaires for hip arthroscopy: a systematic review of the psychometric evidence
Abstract Background Hip arthroscopies are often used in the treatment of intra-articular hip injuries. Patient-reported outcomes (PRO) are an important parameter in evaluating treatment. It is unclear which PRO questionnaires are specifically available for hip arthroscopy patients. The aim of this systematic review was to investigate which PRO questionnaires are valid and reliable in the evaluation of patients undergoing hip arthroscopy. Methods A search was conducted in Pubmed, Medline, CINAHL, the Cochrane Library, Pedro, EMBASE and Web of Science from 1931 to October 2010. Studies assessing the quality of PRO questionnaires in the evaluation of patients undergoing hip arthroscopy were included. The quality of the questionnaires was evaluated by the psychometric properties of the outcome measures. The quality of the articles investigating the questionnaires was assessed by the COSMIN list. Results Five articles identified three questionnaires; the Modified Harris Hip Score (MHHS), the Nonarthritic Hip Score (NAHS) and the Hip Outcome Score (HOS). The NAHS scored best on the content validity, whereas the HOS scored best on agreement, internal consistency, reliability and responsiveness. The quality of the articles describing the HOS scored highest. The NAHS is the best quality questionnaire. The articles describing the HOS are the best quality articles. Conclusions This systematic review shows that there is no conclusive evidence for the use of a single patient-reported outcome questionnaire in the evaluation of patients undergoing hip arthroscopy. Based on available psychometric evidence we recommend using a combination of the NAHS and the HOS for patients undergoing hip arthroscopy.</p
Direct Integration and Non-Perturbative Effects in Matrix Models
We show how direct integration can be used to solve the closed amplitudes of
multi-cut matrix models with polynomial potentials. In the case of the cubic
matrix model, we give explicit expressions for the ring of non-holomorphic
modular objects that are needed to express all closed matrix model amplitudes.
This allows us to integrate the holomorphic anomaly equation up to holomorphic
modular terms that we fix by the gap condition up to genus four. There is an
one-dimensional submanifold of the moduli space in which the spectral curve
becomes the Seiberg--Witten curve and the ring reduces to the non-holomorphic
modular ring of the group . On that submanifold, the gap conditions
completely fix the holomorphic ambiguity and the model can be solved explicitly
to very high genus. We use these results to make precision tests of the
connection between the large order behavior of the 1/N expansion and
non-perturbative effects due to instantons. Finally, we argue that a full
understanding of the large genus asymptotics in the multi-cut case requires a
new class of non-perturbative sectors in the matrix model.Comment: 51 pages, 8 figure
The relationship between priestly motivational styles and personal wellbeing in ministry : exploring the connection between religious orientation and purpose in life among Catholic priests serving in Italy
This study examines the association between priestly motivation (accessed via the psychological notion of religious orientation) and personal wellbeing (accessed via the psychological notion of purpose in life) among a sample of 155 Catholic priests serving in Italy. The data confirm a positive association between intrinsic religious orientation and purpose in life, but a negative association between quest religious orientation and purpose in life. These findings are discussed in light of the expectations placed on Catholic priests by the Church and by society
Results of the randomized phase IIB ARCTIC trial of low dose Rituximab in previously untreated CLL
ARCTIC was a multi-center, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated Chronic Lymphocytic Leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). The trial hypothesized that including mitoxantrone with low-dose rituximab (FCM-miniR) would be non-inferior to FCR. 200 patients were recruited to assess the primary endpoint of complete remission (CR) rates according to IWCLL criteria. Secondary endpoints were progression-free survival (PFS), overall survival (OS), overall response rate, minimal residual disease (MRD) negativity, safety and cost-effectiveness. The trial closed following the pre-planned interim analysis. At final analysis, CR rates were 76% FCR vs 55% FCM-miniR [adjusted odds-ratio: 0.37; 95% CI: 0.19â0.73]. MRD-negativity rates were 54% FCR vs 44% FCM-miniR. More participants experienced Serious Adverse Reactions with FCM-miniR (49%) compared to FCR (41%). There are no significant differences between the treatment groups for PFS and OS. FCM-miniR is not expected to be cost-effective over a lifetime horizon. In summary, FCM-miniR is less well tolerated than FCR with an inferior response and MRD-negativity rate and increased toxicity, and will not be taken forward into a confirmatory trial. The trial demonstrated that oral FCR yields high response rates compared to historical series with intravenous chemotherapy
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL.
In the phase 3 RESONATE(TM) study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors. We report updated results from RESONATE in these traditionally chemotherapy resistant high-risk genomic subgroups at a median follow-up of 19 months. Mutations were detected by Foundation One Heme Panel. Baseline mutations in the ibrutinib arm included TP53 (51%), SF3B1 (31%), NOTCH1 (28%), ATM (19%), and BIRC3 (14%). Median PFS was not reached, with 74% of patients randomized to ibrutinib alive and progression-free at 24 months. The improved efficacy of ibrutinib vs. ofatumumab continues in all prognostic subgroups including del17p and del11q. No significant difference within the ibrutinib arm was observed for PFS across most genomic subtypes, although a subset carrying both TP53 mutation and del17p had reduced PFS compared to patients with neither abnormality. Reduced PFS or OS was not evident in patients with only del17p. PFS was significantly better for ibrutinib-treated patients in second-line vs. later lines of therapy. The robust clinical activity of ibrutinib continues to show ongoing efficacy and acceptable safety consistent with prior reports, independent of various known high-risk mutations
- âŠ